A fat-based fullness signal the body makes in the gut after eating, oleoylethanolamide is taken as a supplement to curb appetite and burn stored fat. Paired with a calorie-controlled diet, it modestly reduces hunger, body weight, waist size, blood sugar, blood fats, and inflammation. It is well tolerated, but the evidence is early and longevity claims rest on animal work. (Full Review)

Protocol

Standard Dose

125 mg

Once or twice daily (125–250 mg/day total)

Timing

~30 min before meals

Before the two largest meals

Dosing Pattern

Split doses

Preferred over a single dose given short duration of action

Time to effect

Appetite & Fullness

Hours to days

Tied to meal timing

Weight & Waist

8–12 weeks

Modest reductions

Metabolic Markers

8–12 weeks

Blood sugar, triglycerides, inflammation

Benefits

High: Reduced body weight & fat mass; appetite suppression & increased satiety

Medium: Improved glycemic control; reduced triglycerides; reduced inflammatory markers; reduced oxidative stress

Low: Improved liver health in fatty liver disease; reduced menstrual pain; improved mood & reduced fatigue

Speculative: Neuroprotection & longevity signaling; atheroprotection & cardiovascular plaque reduction

Contraindications

Pregnancy or breastfeeding

Active eating disorders

Children and adolescents

Key Interactions

Fibrate lipid drugs (fenofibrate, gemfibrozil)

GLP-1 receptor agonists and other appetite-suppressing drugs (semaglutide, liraglutide)

FAAH-inhibitor drugs or supplements

Additive supplements (PEA, berberine, green-tea extract, fish oil)

Risk & Side Effects

Medium: Mild gastrointestinal effects

Low: Excessive appetite suppression in lean users

Speculative: Sedation & reduced movement at high doses; unknown long-term safety; effects on sleep and alertness

Monitoring

Marker	Target	Why
Waist circumference	<94 cm (men), <80 cm (women)	Tracks central fat, OEA's most consistent target
Fasting glucose	75–86 mg/dL	Detects blood-sugar benefit
Fasting insulin	2–6 µIU/mL	Sensitive early marker of insulin resistance
HOMA-IR	<1.0	Summarizes insulin resistance from glucose and insulin
HbA1c	<5.3%	Reflects average blood sugar over 3 months
Triglycerides	<80 mg/dL	OEA's clearest lipid benefit
hs-CRP	<0.5 mg/L	Gauges the anti-inflammatory effect
ALT (liver enzyme)	<25 U/L (men), <20 U/L (women)	Monitors fatty-liver benefit and liver safety

Cadence: Recheck metabolic markers at 8–12 weeks, then every 3–6 months if continued; weekly self-monitoring of weight and appetite during the first month.

Qualitative Assessment

Hunger and cravings: reduced hunger between meals and fewer cravings, especially for sweets
Fullness and portion size: feeling satisfied sooner and eating smaller portions without effort
Energy levels: stable or improved daytime energy rather than fatigue
Mood and well-being: steady or improved mood

Oleoylethanolamide for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment